Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
The efficacy of omalizumab has been extensively investigated in clinical trials in patients with severe persistent allergic (pre-treatment total immunoglobulin E 30–700 IU·mL–1) asthma including the Investigation of Omalizumab in Severe Asthma Treatment (INNOVATE) study, which enrolled patients with...
Main Author: | R. Buhl |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2007-09-01
|
Series: | European Respiratory Review |
Subjects: | |
Online Access: | http://err.ersjournals.com/cgi/content/full/16/104/73 |
Similar Items
-
Age-related differences in IgE between childhood and adulthood allergic asthma: Analysis of NHANES 2005–2006
by: Heping Fang, MMeD, et al.
Published: (2023-12-01) -
Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma
by: Tajiri T, et al.
Published: (2023-01-01) -
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
by: Carlos A. Torres-Duque, et al.
Published: (2022-11-01) -
A review of omalizumab for the management of severe asthma
by: Lin CH, et al.
Published: (2016-07-01) -
Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL
by: Francesco Menzella, MD, et al.
Published: (2023-06-01)